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ABSTRACT
Patients with severe emphysema have limited treatment
options and only derive a small benefit from optimal
medical treatment. The only other therapy to have signif-
icant clinical beneficial effect in emphysema is LVRS but
the perceived risk and invasiveness of surgery has fuelled
bronchoscopic approaches to induce lung volume reduc-
tion. There are multiple bronchoscopic methods for
achieving volume reduction in severe emphysema: EBV,
airway bypass procedure, endobronchial coils, thermal
(vapour) sclerosis and chemical sclerosis (sealants). Opti-
mal patient selection is key to successful patient out-
comes. This review discusses bronchoscopic approaches
for emphysema treatment which has progressed through
clinical trials to clinical practice.
Key words: bronchoscopy, chronic obstructive pulmonary dis-
ease, emphysema, lung volume reduction.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a
chronic, progressive, complex inflammatory lung condi-
tion characterized by airflow limitation, sputum produc-
tion and a decline in exercise tolerance. It is irreversible
and ultimately leads to disabling breathlessness and
reduced life expectancy. It is a heterogeneous disease
predominantly caused by cigarette smoking and, in
some developing economies, by the indoor use of bio-
mass fuels for cooking in poorly ventilated homes. The
condition consists of chronic bronchitis, airflow obstruc-
tion and alveolar destruction.1 This latter component is
known as emphysema, and is defined as the abnormal,
permanent enlargement of air spaces distal to the
terminal bronchioles, accompanied by the destruction of
their walls and without obvious fibrosis. The damage to
the elastin and collagen tissue reduces the tethering of
the bronchioles and in expiration the airways collapse
leading to air trapping. Furthermore, loss of the elastic
recoil also leads to an increase in lung volumes.2 Hyper-
inflation mechanically disadvantages the diaphragm and
intercostal muscles generating an increased work of
breathing. Patients with advanced emphysema are
breathless despite optimal medical treatment (anticho-
linergic drugs, beta-2 agonists, long-acting bronchodila-
tors, inhaled steroids and mucolytics), and whilst oxygen
has some role in palliation, it barely alters the disability
and breathlessness experienced by these patients.2,3
Lung volume reduction surgery (LVRS) was proposed
by Brantigan and Mueller in 1957 on the premise that re-
section of up to 30% of the worst effected lung of an
emphysematous patient in multiple wedge excisions
would permit re-expansion of the remaining healthier tis-
sue, normalize ventilatory mechanics and restore elastic
recoil and airflow.4 Cooper revised the surgical approach
and published his experience demonstrating a lower mor-
tality and significant improvements in quality of life and
pulmonary function.5,6 However, the first report from the
large NETT study stating a higher mortality with LVRS
had the greatest impact and has hampered the progress
and impact of LVRS.7 The subsequent report demonstrat-
ing improvements in mortality in a subgroup with upper
lobe predominant disease and low baseline exercise toler-
ance never quite redressed the negative view around
LVRS that had ensued.8 Despite convincing efficacy evi-
dence, this perception of high morbidity and mortality
had fuelled the development of bronchoscopic
approaches to achieve lung volume reduction.9,10
Several approaches have been developed from the
initial development of artificial airways placed both
endobronchially11 and even transthoracic.12,13 These
implants allow air to escape and bypasses the airways
which are susceptible to expiratory airway collapse in
emphysema. Both therapies showed initial promising
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results with even doubling of pulmonary function
within 24 h of the procedure. However, occlusion of
these artificial airways has limited their development as
a viable therapy.14,15 Hence, the focus of this article is
limited to bronchoscopic approaches for emphysema
treatment which has progressed through clinical trials
to clinical practice. Endobronchial valves (EBV),
endobronchial coils and sclerosant treatments are dis-
cussed (see Table 1 for randomized controlled trials
(RCT) results).
ENDOBRONCHIAL VALVES
The principle of EBV is that if a lobe can be isolated by
placing valves or devices that allow air (and secretions)
to be expelled from that lobe but preventing any ingress
of air into that lobe then that lobe should deflate.
Providing the most damaged air-trapped area is
targeted, this deflation would effectively lead to lung vol-
ume reduction and hence improve chest wall mechanics
and diaphragmatic function.9,16–18 The two main devices
that have been extensively investigated are the Zephyr
EBV by Pulmonx (Redwood City, CA, USA) and the
Spiration Valve System (SVS, previously referred to as
the intrabronchial valve or IBV) by Olympus (Center
Valley, Pennsylvania, USA). Two other devices with only
limited clinical evaluation are the MedLung EBV
(MedLung, Barnaul, Russia) and the Endobronchial
Miyazawa Valve (Novatech, La Ciotat, France).
ZEPHYR EBV
The Zephyr valve is a silicone skin duckbill valve with a
nitinol frame. The nitinol frame allows it to be
Table 1 Change in outcomes following bronchoscopic lung volume reduction treatment options compared to control

















STELVIO24 n = 68
6 months
17.8 74 −14.7
BeLieVeR HIFi23 n = 50
3 months
20.9 33 −5.1
IMPACT25 n = 93
6 months
16.3 28 −7.5
TRANSFORM26 n = 97
6 months
29.3 79 −6.5
LIBERATE27 n = 190
12 months
18 39 −7.1
REACH43 n = 107
6 months
† 36 −10.5




RESET56 n = 46
3 months
14.2 51 −8.1
REVOLENS57 n = 100
12 months
8 2 −9.1













§Six months data (n = 21).
6MWD, 6-min walk distance; FEV1, forced expiratory volume in 1 s; RCT, randomized controlled trial; SGRQ, St George’s Respiratory
Questionnaire.
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compressed and delivered through the instrument
channel of a flexible bronchoscope. The nitinol frame
then expands securing the valve within the airway
(Fig. 1). The zephyr valve is available in two airway
sizes: size 4 (suitable for airway diameters of
4.0–7.0 mm) and size 5 (airway diameter size of
5.5–8.5 mm). Both valve sizes are also available in stan-
dard and low profile lengths. The latter has a shorter
landing zone and allows secure valve placements in
segments with short airways such as the apical segment
of the lower lobe.19,20
There have been six randomized controlled studies
performed with the Zephyr valves in a total of
970 patients (610 were randomized to treatment with
Zephyr valves and 310 to standard of care (SoC)).21–27
The US arm of the VENT study randomized 321 patients
in a 2:1 ratio: 220 EBV and 101 to SoC.21 The study
demonstrated only modest clinical improvements in
forced expiratory volume in 1 s (FEV1) of 6.8% (95% CI:
2.1 to 11.5; P = 0.005), 6-min walk distance (6MWD) of
5.8% (95% CI: 0.5 to 11.2; P = 0.04) equivalent to
19.1 m and St George’s Respiratory Questionnaire
(SGRQ) total score improvement of −3.4 (95% CI: −6.7
to 0.2; P = 0.04) in the treatment group over SoC. The
European arm of the VENT study enrolled 171 patients
and hence did not have sufficient power to achieve sta-
tistical significance.22 It was at this stage that the impact
of collateral ventilation on outcomes was realized espe-
cially as patients treated in the left upper lobe had
much better outcomes than those that received right
upper lobe therapy.19,28,29 Post hoc data analysis
highlighted that individuals with computed tomogra-
phy (CT) evidence of fissure integrity (determined by
visualization as 90% or more complete), a surrogate for
absent interlobar collateral ventilation, experience
much better clinical outcomes. In a subgroup of
122 patients (61 treated and 61 matched control
patients), the changes compared to control were: FEV1
of 24.7%, 6-min walk test (6MWT) of 28 m and SGRQ
of −8.4 points. It also emphasized that correct place-
ment of the valves to completely occlude the lobe was
essential. In the VENT study, approximately one or
more valves was not placed in the optimal position in
40% of patients.19,21 The BeLieVeR HIFi study23 was a
single-centre randomized double-blind sham-
controlled study to evaluate the post hoc findings of
the VENT study. Patients were required to have intact
fissure of the target lobe (proxy for the absence of col-
lateral ventilation) to be eligible. The Chartis system19
was utilized to determine the status of collateral venti-
lation. However, patient inclusion was based on fissure
integrity. The primary endpoint, percentage change in
FEV1 at 3 months, was improved by 24.8% for EBV
recipients compared with 3.9% for subjects in the sham
group (between-group difference of 20.9%; P = 0.033).
Exclusion of six patients who were collateral ventilation
positive or indeterminate following Chartis evaluation
improved the responder rates to EBV treatment
(FEV1% change of 31% at 3 months).
Klooster et al.24 confirmed these findings in a further,
single-centre RCT (the STELVIO trial) of patients with
no collateral ventilation confirmed using the Chartis
system. They recruited 68 patients who had heteroge-
neous emphysema and intact fissures (visually assessed
on CT) and randomized them to treatment or control
in a 1:1 assignment. They excluded patients who were
collateral ventilation positive using the Chartis system
or those patients where the anatomy was not suitable
for complete lobar exclusion with Zephyr valves. The
co-primary endpoints, improvements in FEV1, forced
vital capacity (FVC) and 6MWD at 6 months, were sig-
nificantly greater in the EBV group compared to con-
trols: FEV1 20.9% versus 3.1%, FVC 18.3% versus 4.0%
and 19.6 versus −3.6 m (all <0.01), respectively. This
was accompanied by clinically meaningful improve-
ment in RV of −856 mL, target lobar volume reduction
(TLVR) of 1366 mL and SGRQ of −14.7 points. The
IMPACT study25 was performed in patients with more
homogeneous disease (i.e. less than 10% difference in
the degree of destruction on HRCT between ipsilateral
lobes) and confirmed that this group of patients also
benefit albeit to a lesser degree. Improvements in the
treatment group compared to control were: FEV1 17.1%
and 6MWT 40 versus −9.6 m (all <0.01). The TRANS-
FORM study,26 was a multicentre study where hetero-
geneous emphysema patients were randomized 2:1 to
either valve treatment or SoC. This study was also
important as over half of the centres involved in this
study were centres starting valve treatment. Hence, this
study is close to real clinical practice as possible and
demonstrates that new centres have very similar out-
comes to the experienced centres. At 3 months 55.4%
of EBV versus 6.5% of SoC subjects reached the pri-
mary endpoint of ≥12% improvement in FEV1
(P < 0.001). Improvements in the treatment group com-
pared to control were: FEV1 29.3% and 6MWT 78.7 ver-
sus −6.5 m. These results also confirmed the previous
reported single-centre results from the BeLieVeR HIFi
and STELVIO trials.23,24 The LIBERATE study27 com-
bined all the learning from the previous clinical studies
to determine whether these improvements could be
reproduced in a large multicentre study involving a
majority of US centres and to determine the degree of
Figure 1 Bronchoscopic image of three Zephyr endobronchial
valves (Pulmonx) placed in the right upper lobe segmental ostia
(courtesy of Dirk-Jan Slebos).
Respirology (2020) © 2020 The Authors.
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benefit that was evident at 12 months in this group of
patients with severe emphysema. Furthermore, in this
trial, there was the opportunity to revise the procedure
at 45 days if there was inadequate volume reduction
with evidence of valve mis-placement on a follow-up
HRCT scan. At 12 months, 47.7% of EBV versus 16.8%
of SoC subjects reached the primary endpoint of ≥15%
improvement in FEV1 (P < 0.001). Improvements in the
treatment group compared to control were: FEV1 18%
and 6MWT 39 versus −7.1 m.
A retrospective analysis of 547 patients collected
from four prospective clinical trials was performed by
Koster et al.28 The CT scans were analysed to determine
the fissure integrity score and the Chartis procedure to
determine whether the patients were considered collat-
eral ventilation positive or negative. A positive outcome
was determined as a reduction in the lobar volume of
>350 mL. This allowed thresholds to be determined
and >95% fissure integrity was associated with a posi-
tive outcome in 88% of cases, whereas a fissure that
was less than 80% complete had a negative predictive
value of 93%. The key finding from this study is that all
patients being considered for EBV therapy should have
quantitative CT analysis (Fig. 2) and only those with fis-
sure integrity of 80% or greater should be considered
for a Chartis procedure and subsequent EBV therapy.
Those with fissure that were less than 80% intact
should be considered for alternative modes of lung vol-
ume reduction.
To facilitate fissure status functionality, the Chartis
procedure (Pulmonx) has been developed and is a
catheter-based measurement of expiratory flow origi-
nating from the treatment target or ipsilateral lobe to
assess the functional status of the interlobar fissure.19
Decline of the measured flow pattern (so-called ‘collat-
eral flow negative’) has been shown to qualify patients
for valve treatment. Especially with fissure complete-
ness scores between 80% and 95%, Chartis is of impor-
tant additional value and should be performed to get
solid treatment outcomes.30,31 Performing Chartis can
be challenging during a bronchoscopy under conscious
sedation and spontaneous breathing, but can be as
effectively been performed under general anaesthesia
with positive pressure ventilation as well, greatly facili-
tating ease of use.32 Currently, a new technique to iden-
tify the best suitable lobe to be treated using lobar
oxygen uptake as perfusion surrogate is also under
investigation.33
Improved patient selection has significantly
improved patient outcomes but it is also evident that
the main adverse event as a result of inducing lobar
atelectasis or volume reduction is a secondary pneu-
mothorax.19,34,35 This is presumably due to the
remodelling that occurs with volume loss, further
decreasing pleural pressures and any areas where the
lung is adherent to the pleura may lead to a tear and
cause a pneumothorax. This risk ranges from 20% to
25% in the clinical trials and is reflective in clinical
Figure 2 Example image of a
quantitative HRCT analysis
used for endobronchial valve
treatment (StratX analysis;
Pulmonx). The image shows
the degree of destruction in
the different lobes and fissure
integrity. The numerical values
provide fissure completeness
scores, voxel densities at both
−910 an d-95 Hounsfield units
(HU) and volumes for all the
lobes (used with permission).
LLL, Left Lower Lobe; LUL, left
Upper Lobe; RLL, Right Lower
Lobe; RML, Right Middle Lobe;
RUL, Right Upper Lobe.
© 2020 The Authors.
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practice. The risk is greatest in the first 4 days with over
89% of the pneumothoraces occurring in this
period.19,27 Late pneumothoraces, which are less likely
to be acute tension pneumothoraces, have been
observed and are more likely to be secondary to the
underlying emphysema than the treatment. The most
important aspect in patient care is that the patients are
admitted to hospital for at least 3–4 days after valve
insertion and the medical teams all are aware of the
pneumothorax risk and should be both prepared and
able to manage the event. Less than 5% of treated
patients develop infectious complications, with some of
these involving the treated lobe. Antibiotic treatment is
the SoC but in some situations valve removal may be
required. Valve expectoration is 2–5% in the clinical tri-
als but should be lower with the introduction of low
profile valves with a shorter landing zone.20 Granula-
tion tissue has been observed in some patients and
more unusual adverse events that have been observed
include airway torsion especially with left upper lobe
treatment.19,36 In the longer term a significant survival
benefit has also been shown in those who achieve
EBV-induced lobar atelectasis.37 This was validated in a
larger cohort where 5-year survival was 65.3% with
lobar atelectasis (43.9%, no atelectasis; P = 0.009)
among 449 patients and even out to 10 years in a
smaller retrospective cohort.38 These potential survival
benefits are strengthened by improved predictors of
survival, such as Body-mass index, airflow Obstruction,
Dyspnoea, and Exercise (BODE) and inspiratory capac-
ity (IC)/total lung capacity (TLC) ratio after EBV
treatment,39 and the large series reported form the Hei-
delberg group.40
SPIRATION VALVE SYSTEM
The SVS is not a true valve and utilized a flexible
umbrella device to function as a blocker that is also
supposed to allow secretions out from the edge of the
device (Fig. 3). The original strategy with this device
was to use it as bilateral treatment but without
completely occluding the lobe. This strategy was based
on airflow re-diversion rather than volume reduction
and failed to show clinical benefit.41,42 The strategy was
then aligned with the Zephyr valve to induce unilateral
lobar atelectasis, which was investigated in two RCT.
The first study (the REACH study) was a multicentre
RCT of 99 patients with severe heterogeneous emphy-
sema (≥15% difference between the target and ipsilat-
eral lobes), intact interlobar fissures (≥90%) and
hyperinflation comparing the SVS (n = 66) to SoC
(n = 33).43 The primary endpoint, the between-group
difference of absolute FEV1 changes at 3 months, was
statistically significant favouring the treatment arm
(0.104  0.178 vs 0.003  0.147 L; P = 0.001), although
at 6 months the responder rate for FEV1 ≥ 15% between
the two groups was less marked (41% with SVS vs 21%
with SoC) The pneumothorax rate in this trial was
lower at 7.6%. Longer term data from this trial are not
available. The EMPROVE trial was a similar but larger
US multicentre RCT of 172 patients with severe hetero-
geneous emphysema (≥10% difference between the tar-
get and ipsilateral lobes), intact interlobar fissures
(≥90%) and hyperinflation comparing the SVS (n = 113)
to SoC (n = 59).44 The primary efficacy endpoint, the
difference in the groups’ FEV1 changes at 6 months,
was statistically significant favouring the treatment arm
(0.101 L, 95% CI: 0.060 to 0.141), and a responder rate
for FEV1 ≥ 15% of 36.8% (10.0%, SoC). The primary
safety endpoint, a composite score of respiratory-
related serious adverse events (SAE), was 31.0% in the
treatment arm (11.9%, SoC) largely influenced by a
12.4% incidence of pneumothorax. There were six
deaths (5.3%) in the EBV group and one (1.7%) in the
control arm. Also for this trial, longer follow-up data
have not yet been published, but are expected to
become available looking at its investigators and Food
and Drug Administration (FDA) guidance.
ENDOBRONCHIAL COILS
The RePneu endobronchial coil treatment (PneumRx/
BTG, CA, USA) is a nitinol wire coil-based broncho-
scopic therapy for the treatment of patients with severe
emphysema, being mostly not eligible for LVRS or EBV
treatment.45–47 About 10–14 memory-shaped coils are
placed in the two most diseased emphysematous lobes
under fluoroscopic guidance in two sequential proce-
dures (Fig. 4). Post-procedural pneumothoraces are very
rare in experienced hands (<5%),48 but the treatment
can be complicated by an increase in infectious compli-
cations and coil tension-induced ‘coil-associated
opacity’.47–50 The coil treatment exerts its effects through
a dual mechanism of re-tensioning the lung tissue,
resulting in improved airway tethering, decrease in air-
way resistance with a reduction in hyperinflation as a
consequence, as well as lung volume reduction second-
ary to the coil-associated opacity phenomenon.45,46,51,52
After having established treatment safety, procedural
feasibility and a solid efficacy signal on pulmonary func-
tion, exercise and quality of life in a number of open label
single and multicentre studies,52–55 the coil treatment was
intensively investigated in three RCT (Table 1). In the UK
Figure 3 Bronchoscopic image of one SVS (Spiration Valve
System; Olympus/Spiration) (courtesy of Pallav Shah).
Respirology (2020) © 2020 The Authors.
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multicentre RESET trial, 46 emphysema patients were
randomized to bilateral coil treatment or best medical
care. The primary endpoint, the change from baseline in
SGRQ at 3 months post treatment, showed an of
improvement of −8.4 points (P = 0.04), with subsequent
improvements in both 6MWD (+63.6 m; P < 0.001) and
FEV1 (+10.6%; P < 0.05).
56,57 In the French multicentre
REVOLENS trial, 100 severe emphysema patients were
1:1 randomized to bilateral endobronchial coil treatment
or regular care.58 The primary endpoint, the rate of
responders having an improvement in 6MWD of >54 m,
showed a significant benefit for the coil treated group
(36%) versus the controls (18%) (P = 0.03). Secondary
outcomes showed improvements in FEV1 (+0.09 L;
P = 0.001) and SGRQ (−13.4 points). In the combined
USA/EU FDA-IDE randomized controlled RENEW trial,
the largest of all, 315 severe emphysema patients were
studied.50 In this trial, where over 70% of the included
patients had a homogeneous emphysema distribution,
the 6MWD primary endpoint at 12 months post treat-
ment showed a +14.6 m difference (P = 0.02) between
treatment and control. Also, secondary endpoints signifi-
cantly improved, with a −8.9 points improvement in
SGRQ (P < 0.001), a decrease in RV of −0.31 L (P = 0.01)
and a 7% increase (P < 0.01) in FEV1. Post hoc analysis
showed the best improvements when the RV was >200%,
if there was absence of significant cardiac comorbidity
and chronic bronchitis.48 Similar as with the valve treat-
ments, the post hoc analysis indicates the importance of
using quantitative CT analysis to plan the treatment.49
A few studies did show up to 2- and 3-year treatment
benefit,59,60 with also one study showing the safety and
feasibility of retreating these patients at least 3 years
out.61 Longer term follow-up of the RESET study cohort
has shown that subjects who had a greater than
105 reduction in residual volume also had a survival
benefit at 5 years.62 Future prospective studies, focusing
on better patient selection, mechanism of action and
maybe even updated coil design, will show the poten-
tial of this interesting treatment approach for our non-
valve candidates.
THERMAL VAPOUR ABLATION
Bronchoscopic thermal vapour ablation (BTVA;
Uptake Medical Corporation, Seattle, WA, USA) uti-
lizes thermal energy to induce a localized inflamma-
tory response which in turn leads to fibrotic
remodelling of the treated region and lung volume
reduction.63,64 Thin slice non-contrast inspiratory CT
scans are first evaluated to identify potential treatment
targets and an established algorithm allows an esti-
mate of the weight of the tissue to be treated and
hence the thermal energy required to treat the target
area of the lung. A steam generator delivers the
required calorific energy via a catheter introduced
through the working channel of the bronchoscope.
The catheter has a distal balloon allowing the target
segment of the lung to be isolated whilst the vapour is
being delivered. The procedure is very quick but the
use of general anaesthesia is encouraged as instilla-
tion of steam induces a strong cough reflex and it is
possible for the catheter to become displaced into a
different segmental airway. As the energy calculations
are based on specific lung subsegments, it is essential
that only the selected target area is treated.63
The only multicentre randomized controlled study
(STEP-UP) randomized 70 patients with segmental
vapour ablation (n = 46) to SoC (n = 24).65 The patients
had severe upper lobe-predominant emphysema
(defined as >15% difference between the target and
ipsilateral lobes using quantitative CT analysis). One
segment was targeted during the first treatment session
and up to two segments of a single contralateral lobe in
the second session 13 weeks later. The co-primary end-
points, changes in FEV1 and SGRQ-C scores between
the treatment and control groups at 6 months, were
statistically significant favouring vapour ablation: FEV1
of 14.7% (7.8 to 21.5; P < 0.0001) and SGRQ-C of −9.7
(−15.7 to −3.7; P = 0.0021). Results were greater at
6 months and treated effects persisted through at
12 months.66
The main complication from BTVA is the inflamma-
tory process triggered by the thermal energy. The
response is variable between individuals and in some
patients there is an exaggerated response leading to
fevers and breathlessness secondary to pneumonitis. In
some cases, there was dense consolidation resembling
pneumonia. In the short term, this may be complicated
by bacterial infections. They may also develop exacer-
bations of their underlying COPD. Hence, one option is
to send the patients home with a reserve course of ste-
roids and antibiotics and advice to contact the treating
physician if symptomatic. In the longer term, a few
patients have developed cavities in the treated areas
which can then be colonized with Aspergillus.
Figure 4 Chest X-ray showing the result after a bilateral
endobronchial coil treatment in both the right (11 coils) and left
(12 coils) upper lobes (courtesy of Dirk-Jan Slebos).
© 2020 The Authors.
Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.
Respirology (2020)
6 PL Shah and D-J Slebos
SEALANT
Bronchoscopic biological lung volume reduction, for-
merly known as emphysematous lung sealant, and
now Aeriseal polymeric foam treatment (Pulmonx) is
a synthetic crosslink containing glutaraldehyde and
polyvinyl alcohol causing a local inflammatory
response thereby inducing lung volume reduction.
The two components are immediately, before instal-
lation into the desired segment, premixed to a foam
and then instilled through a dedicated single lumen
catheter. The early studies using Aeriseal showed a
solid efficacy signal,67,68 thereby driving a larger RCT
(ASPIRE),69 which was terminated prematurely due to
lack of financing. The remaining data from this trial
have been published, and repeated increased response
rate in FEV1, quality of life and 6MWD. However, two
patients died in the treatment group, and there was an
SAE hospitalization rate of over 40%. Sclerosing tech-
niques do however have potential in emphysema treat-
ment, and therefor ongoing efforts are underway to test
this application (STAGE trial, NCT02877459). Attempts
are also underway to elegantly use this sclerosis agent
to close small interlobar fissures,70 thus to be able




The meta-analysis of all effective lung volume reduction
interventions has clearly demonstrated that the driver for
clinical benefit is reducing static lung hyperinflation.9 The
clinical studies have demonstrated that for any particular
therapy there is an optimal patient group based on clini-
cal characteristics, comorbidity, degree of hyperinflation
and CT features.19,45,47,71 Hence, patients should be care-
fully evaluated and discussed in a multidisciplinary set-
ting so that the most effective treatment option for the
individual patients is offered.72,73
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